Research summary ·
Efficacy and safety of JAK inhibitors for vitiligo: an updated systematic review and meta-analysis of randomized controlled trials.
Written based on 1 research study on PubMed, searched on 13 Nov 2026.
What was studied
This study pooled results from earlier trials in people with vitiligo. The drugs tested were JAK inhibitors, each used on its own. They were compared with a dummy drug or with other active drugs. In each trial, people were put into groups by chance. The team searched several large research databases up to 11 March 2026. Reviewers checked each trial and its risk of bias. The main measure was how much skin color came back on the face. The team also rated how sure they could be of the evidence.
What they found
The review included trials with 1826 patients in all. JAK inhibitors brought back more face color than a dummy drug. For a smaller level of gain, they did better than tacrolimus. They did not differ clearly from dexamethasone. Serious harms were alike between the groups. The team rated the strength of the evidence as moderate.
What it means for patients
The authors say JAK inhibitors work for vitiligo and are well tolerated. In their view, ruxolitinib put on the skin can be an early option. This is for vitiligo found only in small areas of the face. Drugs taken by mouth look hopeful, in the authors' view.
Why it is not certain yet
Drugs taken by mouth still need safety data over a longer time. The evidence was rated moderate, not high. The result against dexamethasone was not clear. The abstract does not say how long people were followed. A review can only be as good as the studies in it.
Source
Efficacy and safety of JAK inhibitors for vitiligo: an updated systematic review and meta-analysis of randomized controlled trials.
PubMed · PMID 42664062We restate facts from the source record in our own words. The original wording belongs to its publisher.
This page is not medical advice. Talk to your doctor about your own care.
Back to Vitiligo publications